天津医药

天津医药 ›› 2016, Vol. 44 ›› Issue (2): 241-243.doi: 10.11958/59156

• 药物临床观察 • 上一篇    下一篇

大蒜素治疗白塞病的效果和安全性评价

钟建桥 1， 先德海 2   

  1. 1泸州医学院附属医院皮肤科 （邮编 646000）； 2泸州医学院解剖教研室
  • 收稿日期:2015-06-30 修回日期:2015-09-19 出版日期:2016-02-15 发布日期:2016-02-15
  • 基金资助:
    四川省卫生厅科研课题 （100283）

Efficacy and safety of allicin in Behcet′s disease

ZHONG Jianqiao1, XIAN Dehai2   

  1. 1 Department of Dermatology, the Affiliated Hospital of Luzhou Medical College, Luzhou 646000, China; 2 Department of Human Anatomy, Luzhou Medical College
  • Received:2015-06-30 Revised:2015-09-19 Published:2016-02-15 Online:2016-02-15

PDF (PC)

4008

摘要： 目的 评价大蒜素对白塞病 （BD） 的治疗效果和安全性的影响。方法 将 38 例主要累及皮肤黏膜和关节的 BD 患者用随机数字表法分为治疗组 （20 例） 和对照组 （18 例）， 分别予以大蒜素和安慰剂连续口服 12 周， 随访至 16 周。观察 2 组 BD 患者治疗前后临床症状和实验室检测值的变化， 比较 2 组的治疗效果和不良反应。结果 共有 31 例患者完成试验， 治疗组有效率为 88.89%， 明显高于对照组 （7.69%）， 差异有统计学意义； 治疗后治疗组血中白细胞计数（WBC）与治疗前及对照组比较均无明显差异（P > 0.05）， 而红细胞沉降率（ESR）和 C 反应蛋白（CRP）水平则较治疗前及对照组显著降低（P < 0.01）； 尽管大蒜素有一些不良反应， 但大部分患者能耐受且停药后可消退。结论 大蒜素是治疗 BD 的一种安全有效的药物， 疗效明显优于安慰剂， 值得进一步研究和推广。

关键词: 大蒜素, 白塞病, 随机对照试验

Abstract: Objective To evaluate the efficacy and safety of allicin in patients with Behcet′s disease (BD). Methods Thirty-eight patients with BD that was mainly involved skin, mucosa and joints were divided into treatment group (20 cases) and control group (18 cases) by randomized digital table method. Two groups of patients were respectively assigned to receive allicin tablets and identical placebo vehicles for 12 weeks, and were followed up to 16 weeks. The changes of clinical symp⁃ toms and laboratory detection were observed in the time of pretreatment and post-treatment in two groups. Meanwhile, the ef⁃ ficacy and side effects were compared between both groups. Results A total of 31 patients completed the experiment. The effective rate was 88.89% in treatment group, which was significantly higher than that of the control group (7.69%, P < 0.01). After administration of allicin or placebo, there was no significant difference in white blood cell (WBC) count between treat⁃ ment group and control group(P > 0.05). The levels of ESR and CRP were significant lower in treatment group than those in pretreatment and control group (P < 0.01). Although allicin displayed some adverse reactions, most patients could tolerate them, and these side effects tended to dissipate once the drug ceased. Conclusion Allicin is a safe and effective drug in the treatment of BD, which is significantly better than placebo, and is worth to be further researched and promoted.

Key words: Allcin, Behcet′s disease (BD), randomized controlled trials